Stefano Fanti, MD of University of Bologna, Bologna, Italy discusses radiopharmaceutical approval in Europe at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Radiopharmaceuticals play a vital part in the treatment of prostate cancer, however, they are not approved all across Europe. Different countries have different legislation, and some are more restricted than other when it comes to approving radiopharmaceuticals for clinical use. Dr Fanti states that there needs to be a more balanced handling of this situation to ensure patients receive the same treatments across Europe.